The impact of EGFR Exon 20 mutation subtypes on lung cancer prognosis.

被引：0
|
作者：
Xu, Ming
Li, Yingmei
Liu, Danni
Mu, Tianhao
Cheng, Nitao
机构：
[1] Wuhan Univ, Zhongnan Hosp, Dept Thorac Surg, Wuhan, Peoples R China
[2] HaploX Biotechnol, Shenzhen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20557
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EGFR exon 20 insertion mutation in Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Takada, Minoru
    Kawahara, Masaaki
    Kitahara, Naoto
    Tanaka, Hisaichi
    Okumura, Meinoshin
    Matsumura, Akihide
    Luchi, Keiji
    Kawaguchi, Tomoya
    Kawano, Osamu
    Yukiue, Haruhiro
    Yokoyama, Tomoki
    Yano, Motoki
    Fujii, Yoshitaka
    [J]. LUNG CANCER, 2007, 58 (03) : 324 - 328
  • [2] Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation
    Lam, N. S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S510 - S510
  • [3] Is EGFR Exon20 Mutation a Prognostic/Predictive Biomarker in Our Lung Cancer Patients?
    Philip, Deepa S. Joy
    Choughule, Anuradha
    Jambhekar, Nirmala
    Patil, Vijay
    Joshi, Amit
    Naronha, Vanita
    Prabhash, Kumar
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S177 - S177
  • [4] Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation
    Korkmaz, Levent
    Artac, Mehmet
    Karaagac, Mustafa
    Er, Zehra
    Boruban, Melih C.
    Poyraz, Necdet
    Kaya, Bugra
    Tavli, Lema
    Odev, Kemal
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (01): : 64 - 66
  • [5] Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
    Seo, Donghyun
    Lim, Jun Hyeok
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [6] Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma
    Tian, Yingying
    Zhao, Jiuzhou
    Ren, Pengfei
    Wang, Bo
    Zhao, Chengzhi
    Shi, Chao
    Wei, Bing
    Ma, Jie
    Guo, Yongjun
    [J]. PLOS ONE, 2018, 13 (11):
  • [7] The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
    Zhao, Chao
    Jiang, Tao
    Li, Jiayu
    Wang, Yan
    Su, Chunxia
    Chen, Xiaoxia
    Ren, Shengxiang
    Li, Xuefei
    Zhou, Caicun
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1149 - +
  • [8] Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report
    Kim, Jaemin
    Lee, Youngjoo
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (12):
  • [9] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
    van Veggel, B.
    Santos, J. F. Vilacha Madeira R.
    Hashemi, S. M. S.
    Paats, M. S.
    Monkhorst, K.
    Heideman, D. A. M.
    Groves, M.
    Radonic, T.
    Smit, E. F.
    Schuuring, E.
    van der Wekken, A. J.
    de Langen, A. J.
    [J]. LUNG CANCER, 2020, 141 : 9 - 13
  • [10] Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib
    Russell, Molly C.
    Garelli, Alyssa M.
    Reeves, David J.
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (02) : 198 - 206
12345